Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 8/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371799 | 0.89 | PDGFRB (0.51) | METPDGFRBPDGFRAAXLFGFR2 | |
| SCHEMBL371669 | 0.83 | MET (0.48) | METPDGFRBPDGFRAAXL | |
| SCHEMBL3894223 | 0.78 | SRC (0.45) | PDGFRBPDGFRAAXLFGFR2 | |
| SCHEMBL3551410 | 0.77 | HTR1A (0.46) | MET | |
| SCHEMBL632944 | 0.77 | LMNA (0.52) | PDGFRBPDGFRAAXL | |
| SCHEMBL2747292 | 0.77 | PDGFRB (0.59) | METPDGFRBPDGFRAAXLFGFR2 | |
| SCHEMBL14999154 | 0.76 | SRC (0.39) | PDGFRBPDGFRAAXL | |
| SCHEMBL16070093 | 0.76 | EHMT2 (0.50) | PDGFRBPDGFRAFGFR2 | |
| SCHEMBL7755328 | 0.75 | PLA2G2D (0.40) | — | |
| SCHEMBL1889615 | 0.75 | PDGFRA (0.64) | METPDGFRBPDGFRAAXLFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221372-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GlaxoSmithKline Intellectual Property (NO 2.) Limited (GB) | 2014-08-07 | — | — | US | disclosed |
| WO-2014093750-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GLAXOSMITHKLINE LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130252956-A1 | METHODS OF TREATING CANCER | EXELIXIS, INC. | 2013-09-26 | — | — | US | disclosed |
| US-20130150363-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | GLAXOSMITHKLINE (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012071321-A1 | METHOD OF TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2009137429-A1 | METHOD OF TREATING CANCER USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090274693-A1 | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor | EXELIXIS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252956-A1 | METHODS OF TREATING CANCER | HRAS, TP53, HCCS | MET 54/4885PDGFRB 2777/4885PDGFRA 2593/4885 |
| US-20140221372-A1 | METHOD OF ADMINISTRATION AND TREATMENT | MET, SLCO1B3, SLCO2B1 | MET 1/4885PDGFRB 402/4885PDGFRA 519/4885 |
| US-20090274693-A1 | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor | ERBB3, ERBB2, EGFR | MET 8/4885PDGFRB 76/4885PDGFRA 156/4885 |
| US-20130150363-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | ERBB3, ERBB2, EGFR | MET 8/4885PDGFRB 76/4885PDGFRA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.